stockrow
Friday 6 November 2026
Export OMDA’s income statement to Excel — free account
Omada Health, Inc.
OMDA Healthcare Health Information Services
Omada Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $260.2 million, up 53.2% from fiscal 2024.
- Revenue
- +34.2%
- EPS
- +283.3%
- Free cash flow
- +65.8%
Quarter to September 2026, against a year earlier
15.10
3.85
−20.32%
Follow OMDA
Alert me
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 0.00 | 2.22 |
Altman Z-Score |
— | — | 3.98 |
Altman Z″-Score (non-manufacturers) |
— | (9.72) | 2.28 |
P/FCF ratio |
0.00 | 0.00 | 46.55 |
Beneish M-Score |
— | — | (2.59) |
P/Operating CF |
(11.76) | (11.76) | 27.04 |
P/B ratio |
0.00 | 0.00 | 2.52 |
Price to Tangible BV |
0.00 | 0.00 | 2.70 |
EV/Sales |
0.00 | 0.00 | 1.48 |
EV/EBITDA |
0.00 | 0.00 | 0.00 |
EV/Operating CF |
(2.84) | (2.84) | 21.15 |
EV/FCF |
(2.58) | (2.58) | 31.09 |
Quick Ratio |
— | 1.85 | 3.39 |
Current Ratio |
— | 2.10 | 3.60 |
Net Debt/EBITDA |
0.00 | 1.30 | 77.72 |
Debt/Assets |
0.00% | 19.73% | 0.00% |
Debt/Equity |
0.00 | (0.08) | 0.00 |
Asset Turnover |
0.00 | 2.25 | 1.14 |
Operating CF/Net income |
0.74 | 0.73 | (1.43) |
Capex/Depreciation |
(0.44) | (0.49) | (0.64) |
Interest Coverage |
(14.03) | (9.69) | (4.72) |
| 0.00% | 0.00% | 16.52% | |
| 0.00% | (62.48%) | (5.60%) | |
ROIC |
0.00% | 0.00% | (97.89%) |
Return on Tangible Assets |
0.00% | (72.82%) | (6.23%) |
Average Days of Receivables |
0.00 | 50.34 | 48.51 |
Research and Development Expense of Revenue |
27.48% | 21.16% | 15.63% |
Selling, General and Administrative Expense of Revenue |
83.26% | 65.14% | 54.66% |
Intangible Assets out of Total Assets |
0.00 | 0.12 | 0.05 |
Share Based Compensation of Revenue |
7.12% | 5.55% | 4.98% |
Graham Net Nets |
(2.23) | (2.23) | 0.34 |
Graham Number |
0.00 | 0.00 | 0.00 |
Earnings Yield |
(21.69%) | (21.69%) | (8.60%) |
Free Cash Flow Yield |
(29.23%) | (29.23%) | 2.15% |
Revenue per Share |
17.32 | 21.99 | 7.10 |
Operating CF per Share |
(7.01) | (4.43) | 0.50 |
Capex per Share |
(0.41) | (0.50) | (0.16) |
Free Cash Flow per Share |
(7.43) | (4.93) | 0.34 |
Cash per Share |
0.00 | 9.89 | 6.06 |
Shareholders Equity per Share |
0.00 | (49.79) | 6.27 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | (49.79) | 6.27 |
Free Cash Flow |
(52.66) | (38.04) | 12.42 |
Working Capital |
— | 59.11 | 197.21 |
Capital Expenditures |
(2.92) | (3.86) | (5.83) |
Net Current Asset Value |
0.00 | (422.24) | 197.21 |
EV/EBIT |
0.00 | 0.00 | 0.00 |
Capex to Sales |
0.02 | 0.02 | 0.02 |
Price to Operating Income |
0.00 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.00 | 1.39 | 1.15 |
Cash ROIC |
0.00% | 13.67% | 2.75% |
Accounts Receivable Turnover |
0.00 | 0.00 | 8.97 |
Accounts Payable Turnover |
0.00 | 0.00 | 12.36 |
Inventory Turnover |
0.00 | 0.00 | 22.94 |
Average Days of Payables |
0.00 | 22.73 | 42.02 |
Days of Inventory on Hand |
0.00 | 17.98 | 18.34 |
Average Receivables |
— | — | 29.00 |
Average Payables |
— | — | 7.22 |
Average Inventory |
— | — | 3.89 |
Average Assets |
— | 75.45 | 228.15 |
Average Common Equity |
— | — | (77.36) |
Columns are period end dates · fundamentals updated 6 Nov 2026